- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02526862
Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation (PUPPVMNI)
Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation. Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non-Invasive Mechanical Ventilation (NIVM) has turned into a standard in the care of patients with acute respiratory failure. Defined as a support modality to the patient's spontaneous ventilation, it does not use invasive techniques to ventilate, working as an external device named interface or mask, avoiding so the complications associated to the invasive ventilation.
NIVM had been restricted to ICU and Pneumology services, but in the last years it has been extended to ER with good results and it is being also used in the pre-hospital attention and in the home care of chronic patient.
Often, the preferred interface is the oronasal, worst tolerated but associated to best treatment of the acute pathology. In most cases to avoid air leaks, its proper placement generates high pressure on the skin, being able to harm patient's tissues, so that this therapy as intervention for the acute patient has pressure ulcers -PU- as main iatrogenic effect - although 95% of the PU are considered as preventable-.
To diminish the pressure of the mask on the points of the face, nurses protect the most exposed zones with dressings of hydrogel-foam, polyurethane and/or hyperoxygenated fatty acids, trying to prevent PU.
Reviewed studies present a big variability in these practices as well as high dispersion of the results achieved.
Preventive measures are different and even none, as applying the mask or the interface directly could be the most effective treatment in the prevention of PU, avoiding not justified increase of fungible and other resources consumption.
The aim of this study is to test direct application of the mask or interface, as the most efficient intervention, compared with other three usual preventive measures which consist in the use of three different medical devices: autoadhesive polyurethane dressing (Allevyn Thin®), semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®) or hyperoxygenated fatty acids (Linovera®)
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28007
- Emergency and Critical Care. Hospital General Universitario Gregorio Marañón.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults (≥18 years).
- Not tissue injury in face.
- Not structural deformation of the facial anatomy.
Exclusion Criteria:
- Rejects Informed Consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: A-Mask or direct interface
Mask or direct interface
|
|
Active Comparator: B-Autoadhesive polyurethane dressing
Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®).
The dressing will be standardized cut to avoid bias.
The edges shape will be circular.
They will be set in nasal bridge and cheekbones, avoiding frontal level.
It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
|
Protection of the dermis with autoadhesive polyurethane dressing.
The dressing will be standardized cut to avoid bias.
The edges shape will be circular.
They will be set in nasal bridge and cheekbones, avoiding frontal level.
It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
|
Active Comparator: C-Semi-permeable hydrogel-foam
Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®).
The dressing will be standardized cut to avoid bias.
The edges shape will be circular.
They will be set in nasal bridge and cheekbones, avoiding frontal level.
It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
|
Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing.
The dressing will be standardized cut to avoid bias.
The edges shape will be circular.
They will be set in nasal bridge and cheekbones, avoiding frontal level.
It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
|
Active Comparator: D-Hyper hydrogenated fatty acids
Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask.
It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product.
It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
|
Protection of the dermis with hyper hydrogenated fatty acids.
It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product.
It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of PU for each group (mean, standard deviation and quartiles)
Time Frame: First 24 hours after the withdrawal of the treatment
|
Compare the efficacy of the preventive treatments A, B, C and D - previously described-(meaning by efficacy the no occurrence of PU). For definition of PU investigators use the one of the "National Group for the Study and Advice in Pressure Ulcer and Chronic Wounds" (GNEAUPP) |
First 24 hours after the withdrawal of the treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of total NIVM related PU, by observation registers.
Time Frame: 24 hours after the withdrawal of the treatment
|
Total incidence of NIVM related PU within the first 24 hours after the withdrawal of the treatment, registered for the different preventive procedures.
|
24 hours after the withdrawal of the treatment
|
Efficiency of preventive measures for PU related to NIVM, by registering incidence and resources invested -time in hours and consumables in euros- (mean, standard deviation and quartiles for each group)
Time Frame: 24 hours after the withdrawal of the treatment
|
Compare the efficacy and efficiency (cost related efficacy) of the preventive treatments A, B, C and D - previously described
|
24 hours after the withdrawal of the treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Peña-Otero, M.Sc., Nurse. Emergency and Critical Care. Hospital General Universitario Gregorio Marañón. Nursing Faculty. Universidad Rey Juan Carlos. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUPPVMNI_200910
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
Poitiers University HospitalRecruitingAcute Respiratory Failure | Hypoxemic Respiratory FailureFrance
-
Catholic University of the Sacred HeartFisher and Paykel HealthcareCompletedWeaning Failure | Acute Respiratory FailureFrance, Greece, Italy, Spain
-
Hemovent GmbHMAXIS Medical, LLCActive, not recruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory FailureGermany
-
Hospital Clinic of BarcelonaCompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory FailureSpain
-
UPECLIN HC FM Botucatu UnespUnknownExtubation Failure | Acute Respiratory Failure Post ExtubationBrazil
-
Efficacy Care R&D LtdMemorial Hermann Hospital; CRG Medical, Inc.UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest | Acute Respiratory Failure With Hypoxia | Acute Respiratory Failure Requiring Reintubation | Acute... and other conditionsUnited States
-
Siriraj HospitalRecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory FailureThailand
-
Fisher and Paykel HealthcareCentre hospitalier de l'Université de Montréal (CHUM); Institut universitaire...Not yet recruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
University Hospital, AngersNot yet recruitingCardio-Respiratory FailureFrance
-
University Hospital, MotolCompletedRefractory Respiratory FailureCzechia
Clinical Trials on Allevyn Thin®
-
NYU Langone HealthCompleted
-
Charite University, Berlin, GermanyCompletedPressure Ulcer PreventionGermany
-
I.R.A. Istituto Ricerche Applicate S.p.A.Opera CRO, a TIGERMED Group CompanyCompleted
-
Belgium Health Care Knowledge CentreCompleted
-
Smith & Nephew Orthopaedics AGCompletedWoundGermany, France, United Kingdom
-
HealthPartners InstituteTerminated
-
Smith & Nephew, Inc.CompletedLeg Ulcer | Diabetic Foot Ulcer | Pressure UlcerUnited States
-
Smith & Nephew, Inc.CompletedChronic WoundsUnited Kingdom
-
Harvard Medical School (HMS and HSDM)CompletedEdentulous Alveolar RidgeLithuania
-
NYU Langone HealthCompletedRespiratory Aspiration | Deglutition Disorders | Respiratory Distress Syndrome In Premature Infants | Newborn, Premature